BlackRock
WHWK

BlackRock’s Whitehawk Therapeutics WHWK Stock Holding History

BlackRock’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Buy
351,385
+52,374
+18% +$164K ﹤0.01% 4269
2025
Q4 		$724K Buy
299,011
+2,853
+1% +$6.55K ﹤0.01% 4395
2025
Q3 		$563K Sell
296,158
-2,162
-0.7% -$3.98K ﹤0.01% 4430
2025
Q2 		$558K Buy
298,320
+57,071
+24% +$99.3K ﹤0.01% 4412
2025
Q1 		$429K Sell
241,249
-2,641
-1% -$6.9K ﹤0.01% 4437
2024
Q4 		$769K Buy
243,890
+1,002
+0.4% +$2.27K ﹤0.01% 4294
2024
Q3 		$500K Sell
242,888
-77,359
-24% -$125K ﹤0.01% 4328
2024
Q2 		$468K Sell
320,247
-720,759
-69% -$1.34M ﹤0.01% 4361
2024
Q1 		$2.44M Sell
1,041,006
-40,625
-4% -$78.3K ﹤0.01% 3937
2023
Q4 		$2.18M Buy
1,081,631
+75,825
+8% +$318K ﹤0.01% 4009
2023
Q3 		$4.87M Sell
1,005,806
-11,318
-1% -$65.8K ﹤0.01% 3667
2023
Q2 		$6.96M Buy
1,017,124
+140,959
+16% +$1.1M ﹤0.01% 3580
2023
Q1 		$6.34M Sell
876,165
-15,698
-2% -$168K ﹤0.01% 3531
2022
Q4 		$11.4M Buy
891,863
+33,361
+4% +$436K ﹤0.01% 3334
2022
Q3 		$12.1M Sell
858,502
-44,175
-5% -$581K ﹤0.01% 3321
2022
Q2 		$11.1M Buy
902,677
+592,550
+191% +$8.8M ﹤0.01% 3450
2022
Q1 		$5.26M Buy
310,127
+573
+0.2% +$11K ﹤0.01% 3928
2021
Q4 		$7.47M Buy
309,554
+293,304
+1,805% +$7.37M ﹤0.01% 3822
2021
Q3 		$478K Buy
16,250
+177
+1% +$5.39K ﹤0.01% 4767
2021
Q2 		$407K Buy
16,073
+7,715
+92% +$176K ﹤0.01% 4745
2021
Q1 		$162K Buy
8,358
+465
+6% +$10.7K ﹤0.01% 4773
2020
Q4 		$116K Buy
7,893
+272
+4% +$5.82K ﹤0.01% 4556
2020
Q3 		$171K Buy
7,621
+3
+0% +$63 ﹤0.01% 4433
2020
Q2 		$143K Sell
7,618
-4,125
-35% -$54K ﹤0.01% 4433
2020
Q1 		$97K Buy
11,743
+420
+4% +$3.87K ﹤0.01% 4357
2019
Q4 		$106K Buy
11,323
+96
+0.9% +$800 ﹤0.01% 4440
2019
Q3 		$114K Buy
11,227
+212
+2% +$2.35K ﹤0.01% 4424
2019
Q2 		$150K Buy
11,015
+4,853
+79% +$73.6K ﹤0.01% 4406
2019
Q1 		$83K Buy
+6,162
New +$265K ﹤0.01% 4403

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock's WHWK Position: Q1 2026 in Review

BlackRock increased its Whitehawk Therapeutics (WHWK) stake by 18% in Q1 2026, buying an estimated $164K and bringing the position to 351,385 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #4269.

BlackRock first reported a position in WHWK in Q1 2019 and has held it in 29 quarters since. The position peaked at $12.1M in Q3 2022. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • BlackRock held 351,385 shares of Whitehawk Therapeutics worth $1.21M as of Q1 2026.
  • BlackRock bought 52,374 Whitehawk Therapeutics shares in Q1 2026, an estimated $164K.
  • Whitehawk Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4269 holding.
  • BlackRock first reported a position in Whitehawk Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • BlackRock's Whitehawk Therapeutics position peaked at $12.1M in Q3 2022.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.